Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group
- PMID: 17701257
- DOI: 10.1007/s11307-007-0106-3
Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group
Abstract
Purpose: Positron emission tomography, combined with computed tomography (PET/CT) has provided clinicians with useful information regarding the diagnosis, initial staging, restaging, and therapy monitoring of malignancies since the beginning of the current century. Our intent here is to identify the critical steps in clinical workups and follow-up, in the true outpatient clinical setting of a freestanding imaging center, for utilization of PET/CT in four different cancer types.
Methods: The four most common reasons for referrals to our facility were identified by reviewing two years of referral data. They were lung cancer (including solitary pulmonary nodule), lymphomas, breast cancer, and colorectal cancer. A review of published literature from 1996 and later was accepted as evidence of appropriateness for utilizing PET/CT in various clinical scenarios. In addition, a medical advisory board consisting of 15 referring physicians representing various specialties was established to provide practical advice regarding the appropriate use of PET/CT in clinical situations. National Comprehensive Cancer Network (NCCN) guidelines were also referenced to establish a baseline for clinical workups at various stages of disease.
Results: Several inconsistencies were identified among the three primary sources of information leading to the establishment of a standardized algorithm for each cancer type. NCCN data did not always agree with published literature, which was also often different from actual clinical practices of referring physicians. The most common inconsistencies included differing opinions from the referrers vs what was published in the NCCN guidelines, especially with regard to the utilization of PET/CT for applications not yet covered by insurance companies. After a reconciliation of the medical advisory board's clinical practices and several published articles, a consensus was established by the medical advisory board for the use of PET/CT imaging for the four cancer types, enabling us to identify the appropriate timing of PET/CT utilization in patient work-ups.
Conclusions: A PET/CT-centric clinical practice decision tree algorithm can be established by assessing a variety of sources of information. Although published literature and NCCN guidelines offer validated guidance to appropriateness, and third party insurance payors have established their own appropriateness standards, our experience showed that inclusion of practical experience from referring physicians who frequently utilize PET/CT imaging provided additional, useful input.
Similar articles
-
Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry.J Clin Oncol. 2008 May 1;26(13):2155-61. doi: 10.1200/JCO.2007.14.5631. Epub 2008 Mar 24. J Clin Oncol. 2008. PMID: 18362365
-
Oncologic 18F-FDG PET/CT: referring physicians' point of view.J Nucl Med. 2012 Oct;53(10):1499-505. doi: 10.2967/jnumed.111.102228. Epub 2012 Aug 23. J Nucl Med. 2012. PMID: 22917886
-
Quality and consistency of clinical practice guideline recommendations for PET/CT and PET: a systematic appraisal.Eur Radiol. 2023 Nov;33(11):7879-7889. doi: 10.1007/s00330-023-09786-8. Epub 2023 Jun 14. Eur Radiol. 2023. PMID: 37314473
-
Best practices: consensus on performing positron emission tomography-computed tomography for radiation therapy planning and for therapy response assessment.Semin Ultrasound CT MR. 2010 Dec;31(6):506-15. doi: 10.1053/j.sult.2010.10.006. Semin Ultrasound CT MR. 2010. PMID: 21147378 Review.
-
PET/CT for the staging and follow-up of patients with malignancies.Eur J Radiol. 2009 Jun;70(3):382-92. doi: 10.1016/j.ejrad.2009.03.051. Epub 2009 Apr 29. Eur J Radiol. 2009. PMID: 19406595 Review.
Cited by
-
The current role of PET-CT in the characterization of hepatobiliary malignancies.HPB (Oxford). 2009 Feb;11(1):4-17. doi: 10.1111/j.1477-2574.2008.00009.x. HPB (Oxford). 2009. PMID: 19590618 Free PMC article.
-
On the added value of baseline FDG-PET in malignant lymphoma.Mol Imaging Biol. 2010 Apr;12(2):225-32. doi: 10.1007/s11307-009-0259-3. Epub 2009 Oct 7. Mol Imaging Biol. 2010. PMID: 19809855 Free PMC article.
-
The use of systematic review evidence to support the development of guidelines for positron emission tomography: a cross-sectional survey.Eur Radiol. 2021 Sep;31(9):6992-7002. doi: 10.1007/s00330-021-07756-6. Epub 2021 Mar 8. Eur Radiol. 2021. PMID: 33683391
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical